The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients
Open accessAbstract
Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support hematopoietic progenitors in vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment and lessen graft-versus-host disease (GVHD); however, the safety and feasibility of this approach needed to be established. In an open-label, multicenter trial, we coadministered culture-expanded MSCs with HLA-identical sibling-matched HSCs in hematologic malignancy patients. Patients received either bone marrow or peripheral blood stem cells as the HSC source. Patients received 1 of 4 study-specified transplant conditioning regimens and methotrexate (days 1, 3, and 6) and cyclosporine as GVHD prophylaxis. On day 0, patients were given culture-expanded MSCs intravenously (1.0-5.0 x 10(6)/kg) 4 hours before infusion of either bone marrow or peripheral blood stem cells. Forty-six patients (median age, 44.5 years; range, 19-61 years) received MSCs and HLA-matched sibling allografts. MSC infusions were well tolerated, without any infusion-related adverse events. The median times to neutrophil (absolute neutrophil count > or = 0.500 x 10(9)/L) and platelet (platelet count > or = 20 x 10(9)/L) engraftment were 14.0 days (range, 11.0-26.0 days) and 20 days (range, 15.0-36.0 days), respectively. Grade II to IV acute GVHD was observed in 13 (28%) of 46 patients. Chronic GVHD was observed in 22 (61%) of 36 patients who survived at least 90 days; it was extensive in 8 patients. Eleven patients (24%) experienced relapse at a median time to progression of 213.5 days (range, 14-688 days). The probability of patients attaining disease- or progression-free survival at 2 years after MSC infusion was 53%. Cotransplantation of HLA-identical sibling culture-expanded MSCs with an HLA-identical sibling HSC transplant is feasible and seems to be safe, without immediate infusional or late MSC-associated toxicities. The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Caplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Self-citationKrampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E., & Dazzi, F. (2003) · Blood · doi:10.1182/blood-2002-07-2104 · Cited by 1,598
Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., & Guinan, E. C. (2003) · Transplantation · doi:10.1097/01.tp.0000045055.63901.a9 · Cited by 1,500
Deans, R. J., & Moseley, A. B. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00482-3 · Cited by 1,412
Self-citation
Research works printed but not linked: 22
- Almeida-Porada, 1999, Cotransplantation of stroma results in enrichment of engraftment and early expression of donor hematopoietic stem cells in utero, Exp Hematol., 27, 1569, 10.1016/S0301-472X(99)00090-9 · doi:10.1016/s0301-472x(99)00090-9
- Klyushnenkova, 1998, Human mesenchymal stem cells suppress allogeneic T cell responses in vitro, Blood, 92, 642a
- McIntosh, 1999, Suppression of alloreactive T cell responses by human mesenchymal stem cells involves CD8+ cells, Blood, 94, 133a
- O’Flaherty, 1995, Bone marrow stromal function from patients after bone marrow transplantation, Bone Marrow Transplant., 15, 207
- Stute, 2002, Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant, J Hematother Stem Cell Res., 11, 977, 10.1089/152581602321080646 · doi:10.1089/152581602321080646
- Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells) [MPCs], Bone Marrow Transplant., 16, 557
- Copelan, 1993, Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2), Semin Oncol., 20, 33
- Socié, 2001, Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia, Blood, 98, 3569, 10.1182/blood.V98.13.3569 · doi:10.1182/blood.v98.13.3569
- Mills, 1995, BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma, J Clin Oncol., 13, 588, 10.1200/JCO.1995.13.3.588 · doi:10.1200/jco.1995.13.3.588
- Blume, 1993, A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission, Blood, 81, 2187, 10.1182/blood.V81.8.2187.2187 · doi:10.1182/blood.v81.8.2187.2187
- Bacigalupo, 1999, Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT), Bone Marrow Transplant., 24, 653, 10.1038/sj.bmt.1701953 · doi:10.1038/sj.bmt.1701953
- Sullivan, 1981, Chronic graft-versus-host disease in 52 patients, Blood, 57, 267, 10.1182/blood.V57.2.267.267 · doi:10.1182/blood.v57.2.267.267
- Bowden, 1991, Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant, Blood, 78, 246, 10.1182/blood.V78.1.246.246 · doi:10.1182/blood.v78.1.246.246
- Vigorito, 1998, A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies, Bone Marrow Transplant., 22, 1145, 10.1038/sj.bmt.1701510 · doi:10.1038/sj.bmt.1701510
- Schmitz, 1998, Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia, Bone Marrow Transplant., 21, 995, 10.1038/sj.bmt.1701234 · doi:10.1038/sj.bmt.1701234
- Blaise, 2000, Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia, J Clin Oncol., 18, 537, 10.1200/JCO.2000.18.3.537 · doi:10.1200/jco.2000.18.3.537
- Russell, 1999, Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia, Bone Marrow Transplant., 24, 1177, 10.1038/sj.bmt.1702051 · doi:10.1038/sj.bmt.1702051
- Champlin, 2000, Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation, Blood, 95, 3702
- Solano, 1998, Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT, Bone Marrow Transplant., 22, 1129, 10.1038/sj.bmt.1701500 · doi:10.1038/sj.bmt.1701500
- Heldal, 2000, A randomised study of allogeneic transplantation with stem cells from blood or bone marrow, Bone Marrow Transplant., 25, 1129, 10.1038/sj.bmt.1702422 · doi:10.1038/sj.bmt.1702422
- Lazarus, 2001, Culture-expanded human marrow-derived MSCs in clinical hematopoietic stem cell transplantation, Graft, 3, 329
- Kumar, 2002, Omission of day +11 methotrexate for graft-versus-host disease prophylaxis after allogeneic BMT increases the risk of severe acute graft-versus-host disease, Bone Marrow Transplant., 30, 161, 10.1038/sj.bmt.1703616 · doi:10.1038/sj.bmt.1703616
Cited by
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Self-citationChamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0197 · Cited by 2,381
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine
Caplan, A. I. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21200 · Cited by 1,956
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Mesenchymal Stromal Cells: Current Understanding and Clinical Status
Salem, H. K., & Thiemermann, C. (2010) · Stem Cells · doi:10.1002/stem.269 · Cited by 915
Mesenchymal Stem Cells: Mechanisms of Inflammation
Singer, N. G., & Caplan, A. I. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130230 · Cited by 851
Mesenchymal Stem Cells as Therapeutics
Parekkadan, B., & Milwid, J. M. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105309 · Cited by 759
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0319 · Cited by 722
Immunomodulation by mesenchymal stem cells and clinical experience
Le Blanc, K., & Ringdén, O. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01844.x · Cited by 720
Yañez, R., Lamana, M. L., García‐Castro, J., Colmenero, I., Ramírez, M., & Bueren, J. A. (2006) · STEM CELLS · doi:10.1634/stemcells.2006-0228 · Cited by 719
Lee, R. H., Seo, M. J., Reger, R. L., Spees, J. L., Pulin, A. A., Olson, S. D., & Prockop, D. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608249103 · Cited by 710
Sarcoma Derived from Cultured Mesenchymal Stem Cells
Tolar, J., Nauta, A. J., Osborn, M. J., Panoskaltsis Mortari, A., McElmurry, R. T., Bell, S., Xia, L., Zhou, N., Riddle, M., Schroeder, T. M., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2005-0620 · Cited by 639
Schallmoser, K., Bartmann, C., Rohde, E., Reinisch, A., Kashofer, K., Stadelmeyer, E., Drexler, C., Lanzer, G., Linkesch, W., & Strunk, D. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01220.x · Cited by 503
Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke
Honmou, O., Houkin, K., Matsunaga, T., Niitsu, Y., Ishiai, S., Onodera, R., Waxman, S. G., & Kocsis, J. D. (2011) · Brain · doi:10.1093/brain/awr063 · Cited by 494
Liotta, F., Angeli, R., Cosmi, L., Filì, L., Manuelli, C., Frosali, F., Mazzinghi, B., Maggi, L., Pasini, A., Lisi, V., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0454 · Cited by 485
Mazini, L., Rochette, L., Amine, M., & Malka, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102523 · Cited by 445
Bai, L., Lennon, D. P., Caplan, A. I., DeChant, A., Hecker, J., Kranso, J., Zaremba, A., & Miller, R. H. (2012) · Nature Neuroscience · doi:10.1038/nn.3109 · Cited by 421
Immune modulation by mesenchymal stem cells
Rasmusson, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.019 · Cited by 374
Mesenchymal stromal cell ‘licensing’: a multistep process
Krampera, M. (2011) · Leukemia · doi:10.1038/leu.2011.108 · Cited by 358
Haniffa, M. A., Wang, X.-N., Holtick, U., Rae, M., Isaacs, J. D., Dickinson, A. M., Hilkens, C. M. U., & Collin, M. P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1595 · Cited by 346
Osteoinduction: A Review of Old Concepts with New Standards
Miron, R. J., & Zhang, Y. F. (2012) · Journal of Dental Research · doi:10.1177/0022034511435260 · Cited by 334
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Weiss, D. J., Kolls, J. K., Ortiz, L. A., Panoskaltsis-Mortari, A., & Prockop, D. J. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200804-037dw · Cited by 309
von Bonin, M., Stölzel, F., Goedecke, A., Richter, K., Wuschek, N., Hölig, K., Platzbecker, U., Illmer, T., Schaich, M., Schetelig, J., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.316 · Cited by 306
Bernardo, M. E., Avanzini, M. A., Perotti, C., Cometa, A. M., Moretta, A., Lenta, E., Del Fante, C., Novara, F., de Silvestri, A., Amendola, G., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20911 · Cited by 277
The journey of islet cell transplantation and future development
Gamble, A., Pepper, A. R., Bruni, A., & Shapiro, A. M. J. (2018) · Islets · doi:10.1080/19382014.2018.1428511 · Cited by 171
Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles
Hall, B., Dembinski, J., Sasser, A., Studeny, M., Andreeff, M., & Marini, F. (2007) · International Journal of Hematology · doi:10.1532/ijh97.06230 · Cited by 171
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“Several studies have investigated the effects of BM-MSC and HSC co-transplantation to facilitate engraftment or reduce graftversus-host disease into patients treated for hematopoietic malignancies [16, 22, 23].”
BackgroundMethodMajore, I., Moretti, P., Stahl, F., Hass, R., & Kasper, C. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9165-y · Cited by 167
Immune properties of mesenchymal stem cells
Sotiropoulou, P. A., & Papamichail, M. (2007) · Methods in Molecular Biology · doi:10.1007/978-1-59745-536-7_16 · Cited by 57
Horwitz, E. M., Andreef, M., & Frassoni, F. (2007) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.10.016 · Cited by 31
Metadata
- Authors
- Lazarus, H. M., Koc, O. N., Devine, S. M., Curtin, P., Maziarz, R. T., Holland, H. K., Shpall, E. J., McCarthy, P., Atkinson, K., Cooper, B. W., Gerson, S. L., Laughlin, M. J., Loberiza, F. R., Moseley, A. B., & Bacigalupo, A.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 11
- Issue
- 5
- Pages
- 389-398
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2100764718
- Cited by
- 803
- References
- 44
- FWCI
- 34.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3631 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.